IL301466A - Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic capillary dilatation - Google Patents
Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic capillary dilatationInfo
- Publication number
- IL301466A IL301466A IL301466A IL30146623A IL301466A IL 301466 A IL301466 A IL 301466A IL 301466 A IL301466 A IL 301466A IL 30146623 A IL30146623 A IL 30146623A IL 301466 A IL301466 A IL 301466A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- hht
- subject
- treatment
- telangiectasia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2015536.2A GB2600384A (en) | 2020-09-30 | 2020-09-30 | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
| PCT/EP2021/076811 WO2022069552A1 (en) | 2020-09-30 | 2021-09-29 | Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL301466A true IL301466A (en) | 2023-05-01 |
Family
ID=73197201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL301466A IL301466A (en) | 2020-09-30 | 2021-09-29 | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic capillary dilatation |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12466839B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4221713A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7900827B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230080448A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116419924A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021352108B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023004885A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3192433A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2023000926A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2600384A (cg-RX-API-DMAC7.html) |
| IL (1) | IL301466A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002996A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022069552A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2600384A (en) | 2020-09-30 | 2022-05-04 | Vaderis Therapeutics Ag | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
| WO2026038045A1 (en) | 2024-08-15 | 2026-02-19 | Almac Discovery Limited | Crystalline forms of 6-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1h-pyrido[2,3-b][1,4]oxazin-2(3h)-one salts and free base |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI301760B (en) | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
| JP2008524339A (ja) | 2004-12-15 | 2008-07-10 | メルク エンド カムパニー インコーポレーテッド | Akt活性のインヒビター |
| WO2006135627A2 (en) | 2005-06-10 | 2006-12-21 | Merck & Co., Inc. | Inhibitors of akt activity |
| CA2656507C (en) | 2006-07-17 | 2012-03-20 | Amgen Inc. | Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors |
| EP2120951A4 (en) | 2006-12-06 | 2012-02-15 | Merck Sharp & Dohme | HAMMER OF ACT ACTIVITY |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
| JP2011522047A (ja) | 2008-06-03 | 2011-07-28 | メルク・シャープ・エンド・ドーム・コーポレイション | Akt活性の阻害剤 |
| US8207169B2 (en) | 2008-06-03 | 2012-06-26 | Msd K.K. | Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D |
| EP2116237A1 (en) | 2008-08-05 | 2009-11-11 | Polichem SA | Compositions for treating rosacea comprising chitosan and a dicarboxylic acid |
| US8957064B2 (en) | 2009-02-13 | 2015-02-17 | Bayer Intellectual Property Gmbh | Fused pyrimidines |
| GB0922589D0 (en) | 2009-12-23 | 2010-02-10 | Almac Discovery Ltd | Pharmaceutical compounds |
| MX336865B (es) | 2011-04-07 | 2016-02-04 | Bayer Pharma AG | Imidazopiridazinas como inhibidores de quinasa akt. |
| EP3294314A4 (en) | 2015-05-15 | 2019-01-16 | Memorial Sloan Kettering Cancer Center | USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES |
| EP3678666B1 (en) | 2017-09-07 | 2025-07-09 | Augusta University Research Institute, Inc. | Specific akt3 activator and uses thereof |
| GB2600384A (en) | 2020-09-30 | 2022-05-04 | Vaderis Therapeutics Ag | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
-
2020
- 2020-09-30 GB GB2015536.2A patent/GB2600384A/en not_active Withdrawn
-
2021
- 2021-09-29 KR KR1020237014688A patent/KR20230080448A/ko active Pending
- 2021-09-29 CA CA3192433A patent/CA3192433A1/en active Pending
- 2021-09-29 CN CN202180066598.2A patent/CN116419924A/zh active Pending
- 2021-09-29 JP JP2023519016A patent/JP7900827B2/ja active Active
- 2021-09-29 US US18/247,261 patent/US12466839B2/en active Active
- 2021-09-29 EP EP21789616.6A patent/EP4221713A1/en active Pending
- 2021-09-29 IL IL301466A patent/IL301466A/en unknown
- 2021-09-29 BR BR112023004885A patent/BR112023004885A2/pt unknown
- 2021-09-29 WO PCT/EP2021/076811 patent/WO2022069552A1/en not_active Ceased
- 2021-09-29 AU AU2021352108A patent/AU2021352108B2/en active Active
- 2021-09-29 MX MX2023002996A patent/MX2023002996A/es unknown
-
2023
- 2023-03-29 CL CL2023000926A patent/CL2023000926A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021352108A9 (en) | 2024-05-23 |
| EP4221713A1 (en) | 2023-08-09 |
| MX2023002996A (es) | 2023-05-03 |
| CN116419924A (zh) | 2023-07-11 |
| CL2023000926A1 (es) | 2023-11-03 |
| JP2023543993A (ja) | 2023-10-19 |
| US20240092801A1 (en) | 2024-03-21 |
| CA3192433A1 (en) | 2022-04-07 |
| JP7900827B2 (ja) | 2026-08-05 |
| BR112023004885A2 (pt) | 2023-04-18 |
| GB202015536D0 (en) | 2020-11-11 |
| US12466839B2 (en) | 2025-11-11 |
| AU2021352108B2 (en) | 2026-04-02 |
| AU2021352108A1 (en) | 2023-05-11 |
| WO2022069552A1 (en) | 2022-04-07 |
| KR20230080448A (ko) | 2023-06-07 |
| GB2600384A (en) | 2022-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2935248B1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| CA3052625A1 (en) | Compositions and methods for treating heart failure | |
| JP2007502300A (ja) | Gsk−3インヒビターおよびその使用 | |
| AU2021352108B2 (en) | Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia | |
| AU2018356430A1 (en) | Aromatic sulfonamide derivatives for the treatment of Ischemic Stroke | |
| JP6587637B2 (ja) | カルボキサミド誘導体 | |
| AU2017281980B2 (en) | Wnt inhibitors for use in the treatment of fibrosis | |
| CN110325523B (zh) | 作为缓激肽b1受体拮抗剂的羧酸芳族酰胺 | |
| JP2011502991A (ja) | 骨癌並びに骨癌に伴う骨喪失及び骨痛の処置又は予防のためのcfms阻害物質の使用 | |
| JP7713972B2 (ja) | 線維性疾患治療用医薬組成物 | |
| WO2017157992A1 (en) | Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders | |
| EP4182311B1 (en) | 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases | |
| EA049324B1 (ru) | Аллостерические ингибиторы akt для применения в лечении наследственной геморрагической телеангиэктазии | |
| RU2791639C2 (ru) | Средство, увеличивающее мозговой кровоток | |
| HK40074977A (en) | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor | |
| HK40074982A (en) | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor | |
| WO2001001981A1 (fr) | Antagonistes de recepteur de vegf | |
| HK40074980A (en) | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor | |
| HK40035558A (en) | Aromatic sulfonamide derivatives for the treatment of ischemic stroke | |
| HK40011855A (en) | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor | |
| JPWO2001058489A1 (ja) | 術後ストレス予防・治療剤 | |
| KR20140038210A (ko) | 아나그렐리드를 포함하는 류마티스 관절염의 예방 또는 치료용 약학 조성물 |